[go: up one dir, main page]

BR0211228A - Composto, composição farmacêutica e seus usos - Google Patents

Composto, composição farmacêutica e seus usos

Info

Publication number
BR0211228A
BR0211228A BR0211228-0A BR0211228A BR0211228A BR 0211228 A BR0211228 A BR 0211228A BR 0211228 A BR0211228 A BR 0211228A BR 0211228 A BR0211228 A BR 0211228A
Authority
BR
Brazil
Prior art keywords
group
substituted
aliphatic
attached
aliphatic group
Prior art date
Application number
BR0211228-0A
Other languages
English (en)
Inventor
Keizo Koya
Lijun Sun
Shoujun Chen
Noriaki Tatsuta
Yaming Wu
Mitsunori Ono
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of BR0211228A publication Critical patent/BR0211228A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A45—HAND OR TRAVELLING ARTICLES
    • A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
    • A45D8/00—Hair-holding devices; Accessories therefor
    • A45D8/004—Hair-holding devices; Accessories therefor with decorative arrangements or form
    • A45D8/006—Interchangeable ornaments attached to hair holding devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA E SEUS USOS". Divulga-se um composto representado pela fórmula estrutural (I): Y é uma ligação covalente de um grupo hidrocarbila de cadeia normal substituído ou não substituído. Ademais, Y, unido com ambos os grupos >C=Z aos quais está ligado, é um grupo aromático substituído ou não substituído. Preferivelmente, Y é uma ligação covalente ou -C(R~ 7~R~ 8~)-. R~ 1~ é um grupo alifático, grupo alifático substituído, grupo heterocíclico não aromático, ou grupo heterocíclico aromático substituído. R~ 2~-R~ 4~ são independentemente -H, grupo alifático, grupo alifático substituído, grupo heterocíclico não aromático, grupo heterocíclico não aromático substituído, grupo arila ou grupo arila substituído, ou R~ 1~ e R~ 3~ unidos com os átomos de carbono e nitrogênio aos quais estão ligados, e/ou R~ 2~ e R~ 4~ unidos com os átomos de carbono e nitrogênio aos quais estão ligados, formam um anel heterocíclico não aromático opcionalmente fundido a um anel aromático. R~ 5~-R~ 6~ são independentemente -H, grupo alifático, grupo alifático substituído, grupo arila ou grupo arila substituído. R~ 7~ e R~ 8~ são cada um independentemente -H, grupo alifático ou alifático substituído, ou R~ 7~ é -H e R~ 8~ é um grupo arila ou arila substituído, ou R~ 7~ e R~ 8~ unidos, formam um grupo alquileno substituído ou não substituído de C~ 2~-C~ 6~- Z é =O ou =S. Divulgam-se também composições farmacêuticas compreendendo o composto da invenção presente e um diluente ou veículo farmaceuticamente aceitável.
BR0211228-0A 2001-07-10 2002-07-10 Composto, composição farmacêutica e seus usos BR0211228A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30425201P 2001-07-10 2001-07-10
US36193602P 2002-03-06 2002-03-06
PCT/US2002/021714 WO2003006428A1 (en) 2001-07-10 2002-07-10 Taxol enhancer compounds

Publications (1)

Publication Number Publication Date
BR0211228A true BR0211228A (pt) 2004-08-10

Family

ID=26973914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211228-0A BR0211228A (pt) 2001-07-10 2002-07-10 Composto, composição farmacêutica e seus usos

Country Status (20)

Country Link
US (4) US6762204B2 (pt)
EP (2) EP1406870B1 (pt)
JP (1) JP4344234B2 (pt)
KR (2) KR100991325B1 (pt)
CN (1) CN1308302C (pt)
AT (2) ATE448199T1 (pt)
AU (1) AU2002354641B2 (pt)
BR (1) BR0211228A (pt)
CA (1) CA2454120C (pt)
DE (1) DE60234345D1 (pt)
ES (1) ES2395141T3 (pt)
HK (1) HK1060117A1 (pt)
IL (2) IL159772A0 (pt)
IS (1) IS2718B (pt)
MX (1) MXPA04000243A (pt)
NO (1) NO333230B1 (pt)
NZ (1) NZ530964A (pt)
TW (1) TWI297335B (pt)
WO (1) WO2003006428A1 (pt)
ZA (1) ZA200401054B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
CA2470826A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
AU2006228035B2 (en) * 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
DK1781604T3 (da) * 2004-06-23 2013-09-16 Synta Pharmaceuticals Corp Bis(thio-hydrazid-amid)-salte til behandling af cancere
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
WO2006055747A2 (en) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
AU2005232302B2 (en) 2005-02-14 2011-08-18 Konami Australia Pty Ltd Gaming Machine with runs of symbols
WO2006113493A2 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
EP1877048A1 (en) * 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Combination cancer therapy with bis(thiohydrazide) amide compounds
EP1871350A1 (en) * 2005-04-15 2008-01-02 Synta Pharmaceuticals Corporation Methods of increasing natural killer cell activity for therapy
BRPI0611262A2 (pt) * 2005-05-16 2010-08-24 Synta Pharmaceuticals Corp mÉtodos de preparaÇço de um di-sal de bis (tio-hidrazida amida)
CN101242820A (zh) * 2005-08-16 2008-08-13 辛塔制药公司 双（硫酰肼酰胺）调配物
AU2007288339B2 (en) * 2006-08-21 2011-08-18 Synta Pharmaceuticals Corp. Compounds for treatment of proliferative disorders
EP2074097A2 (en) 2006-08-21 2009-07-01 Synta Pharmaceuticals Corporation Compounds for treating proliferative disorders
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
US20080226588A1 (en) * 2006-08-21 2008-09-18 Mcleod Matthew Treating melanoma with bis(thiohydrazide amides)
JP2010502616A (ja) * 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
WO2008033494A2 (en) * 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8633323B2 (en) * 2008-03-31 2014-01-21 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
CA2740925A1 (en) 2008-10-22 2010-04-29 Synta Pharmaceuticals Corp. Transition metal complexes of a bis[thiohydrazide amide] compound
BRPI0919720A2 (pt) 2008-10-22 2015-12-08 Synta Pharmaceuticals Corp complexos de metal de transição de compostos bis-[tio hidrazida amida
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
JP5631327B2 (ja) 2008-12-01 2014-11-26 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
WO2011069159A2 (en) 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
AU2012335105A1 (en) 2011-11-10 2014-06-19 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
WO2013103795A1 (en) 2012-01-05 2013-07-11 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3357956A (en) * 1965-03-30 1967-12-12 Du Pont Polymeric 1, 3, 4-thiadiazoles and the process for their preparation
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (pt) 1973-12-17 1975-07-21
US4822777A (en) 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
WO1994010095A1 (de) * 1992-10-23 1994-05-11 Leca Deutschland Gmbh Offenporige mineralische schüttstoffe mit immobilisierten mikroorganismen, deren herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE69433723T3 (de) 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
BR9507914A (pt) 1994-06-03 1997-09-23 Basf Ag Carbamoil-carbo hidrazida processo para preparar carbamoil-carbo-hidrazida composição adequada e processo para controlar fungos nocivos uso da carbamoil-carbo-hidrazida e amino-ácido-hidrazida
AU4482996A (en) * 1995-09-22 1997-04-09 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
US7360084B1 (en) * 2000-05-15 2008-04-15 Nortel Networks Limited System, device, and method for controlling access in a multicast communication network
EP1164126A1 (de) 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
EP1360173A2 (en) * 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
CA2445967A1 (en) 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
WO2002094259A1 (en) 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US20050154039A1 (en) 2001-11-28 2005-07-14 Marie-Odile Glacera Contour 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1385311B1 (en) * 2002-07-23 2008-05-28 Matsushita Electric Industrial Co., Ltd. Terminal apparatus, communication method, and communication system for authentication of users in a user group in a network
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
CA2515726C (en) 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
GB2400526B (en) * 2003-04-08 2005-12-21 Hewlett Packard Development Co Cryptographic key update management
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005046126A1 (en) * 2003-10-31 2005-05-19 Juniper Networks, Inc. Secure transport of multicast traffic
KR100544347B1 (ko) 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
JP2007530589A (ja) 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
TWI278820B (en) * 2004-06-07 2007-04-11 Hannstar Display Corp Impulse driving method and apparatus for liquid crystal device
DK1781604T3 (da) * 2004-06-23 2013-09-16 Synta Pharmaceuticals Corp Bis(thio-hydrazid-amid)-salte til behandling af cancere
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
WO2006055747A2 (en) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
US20060167106A1 (en) 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
EP1871350A1 (en) 2005-04-15 2008-01-02 Synta Pharmaceuticals Corporation Methods of increasing natural killer cell activity for therapy
EP1877048A1 (en) 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Combination cancer therapy with bis(thiohydrazide) amide compounds
BRPI0611262A2 (pt) 2005-05-16 2010-08-24 Synta Pharmaceuticals Corp mÉtodos de preparaÇço de um di-sal de bis (tio-hidrazida amida)
CN101242820A (zh) * 2005-08-16 2008-08-13 辛塔制药公司 双（硫酰肼酰胺）调配物
KR100724935B1 (ko) * 2005-09-15 2007-06-04 삼성전자주식회사 컨텐츠 보호를 위한 개체 간 연동 방법 및 장치, 그리고 그시스템
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2007288334A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
EP2074097A2 (en) 2006-08-21 2009-07-01 Synta Pharmaceuticals Corporation Compounds for treating proliferative disorders
US20080226588A1 (en) * 2006-08-21 2008-09-18 Mcleod Matthew Treating melanoma with bis(thiohydrazide amides)
US20080057917A1 (en) * 2006-08-30 2008-03-06 Daniela Oria Service availability update for a user having a prepaid account at a service provider capable of providing one or more services over a communications network
JP2010502616A (ja) * 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
AU2007294969A1 (en) * 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
AU2007294752A1 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
WO2008033494A2 (en) 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
KR100816561B1 (ko) * 2006-11-24 2008-03-25 한국정보보호진흥원 외래 키를 이용한 모바일 멀티캐스트 키 관리 방법
US20090093538A1 (en) 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
TW200940050A (en) 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)
EP2225201A2 (en) 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)

Also Published As

Publication number Publication date
ES2395141T3 (es) 2013-02-08
ATE448199T1 (de) 2009-11-15
MXPA04000243A (es) 2005-03-07
IL159772A (en) 2011-02-28
KR20040026678A (ko) 2004-03-31
EP2100605A1 (en) 2009-09-16
EP1406870A1 (en) 2004-04-14
KR101092139B1 (ko) 2011-12-12
NZ530964A (en) 2005-08-26
KR100991325B1 (ko) 2010-11-02
EP2100605B1 (en) 2011-09-07
NO333230B1 (no) 2013-04-15
HK1060117A1 (en) 2004-07-30
IS7102A (is) 2004-01-09
ZA200401054B (en) 2005-08-31
CN1308302C (zh) 2007-04-04
IL159772A0 (en) 2004-06-20
US20040235909A1 (en) 2004-11-25
US6762204B2 (en) 2004-07-13
AU2002354641B2 (en) 2005-06-02
EP1406870B1 (en) 2009-11-11
CA2454120A1 (en) 2003-01-23
US7001923B2 (en) 2006-02-21
TWI297335B (en) 2008-06-01
US20030045518A1 (en) 2003-03-06
NO20040096L (no) 2004-02-05
WO2003006428A1 (en) 2003-01-23
IS2718B (is) 2011-02-15
EP2100605B9 (en) 2012-05-09
JP4344234B2 (ja) 2009-10-14
CA2454120C (en) 2011-02-01
US7368473B2 (en) 2008-05-06
DE60234345D1 (de) 2009-12-24
CN1553894A (zh) 2004-12-08
US7750042B2 (en) 2010-07-06
ATE523194T1 (de) 2011-09-15
JP2004534846A (ja) 2004-11-18
KR20100066589A (ko) 2010-06-17
US20080242702A1 (en) 2008-10-02
US20060116374A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
BR0211228A (pt) Composto, composição farmacêutica e seus usos
BR0211227A (pt) Composto, composição farmacêutica e seus usos
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
ES2192081T3 (es) Derivados de purina antivirales.
FI950016A0 (fi) Heterosykliset yhdisteet lääkeaineena
HK1084024A1 (en) Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
IL93816A0 (en) Acryloyl substituted pyrrole derivatives,their preparation and pharmaceutical compositions containing them
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
MX9602979A (es) Compuestos heterociclicos terapeuticos.
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
FR2771412B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0214488A (pt) Derivados de benzotiazol
MX15697A (es) Derivados heterotetraciclicos de lactama y procesopara su preparacion
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
AR045154A1 (es) Compuestos piperidinicos 1,4-disustituidos, su preparacion, composiciones que los contienen, y su uso
DE69904025D1 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
DK378087A (da) Tetracycliske indolderivater
AR052397A1 (es) Derivados de heterociclos nitrogenados puenteados antagonistas de ccr-1, procesos de preparacion y composiciones farmaceuticas.
AR041688A1 (es) Compuestos de imidazolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
GT199500021A (es) Procedimiento para la preparacion de nuevos derivados de erictromicina y su aplicacion como medicamentos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]